Theravance Biopharma, Inc. (TBPH)
19.07
+0.01
(+0.05%)
USD |
NASDAQ |
Feb 25, 16:00
19.17
+0.10
(+0.52%)
After-Hours: 20:00
Theravance Biopharma Research and Development Expense (Quarterly) : 7.707M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 68.85M |
| Nektar Therapeutics | 27.25M |
| Innoviva, Inc. | 13.67M |
| Oramed Pharmaceuticals, Inc. | 1.153M |
| Moderna, Inc. | 708.00M |